Cancer clinical trials in the region Hauts-de-France
333 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 2
Lymphoma
#NCT06558604
#2023-506706-40-00
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma
Required disease stage
Early (stage I and II)
Disseminated (stage III and IV)
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min
50-60 ml/min
30-50 ml/min
Required number of previous lines of therapy
1
Required previous treatments
Chemotherapy
Targeted therapy
Excluded previous treatments
Bispecific T-cell engager antibodies
13 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 2
Head and neck cancer
#NCT06172478
#2023-507641-29-00
Carcinomes épidermoïdes de la tête et du cou
Required histologic types
Oral cavity
Oropharynx
Hypopharynx
Larynx
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Daiichi Sankyo
Phase 2
Acute leukemia
#NCT07007052
#2024-511003-42-00
Required histologic types
Blastic plasmacytoid dendritic cell neoplasm (BPDC...
Required renal function statuses
> 60 ml/min
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
8 recruiting sites
French Innovative Leukemia Organisation (FILO)
Phase 2
Skin cancer
#NCT06172478
#2023-507641-29-00
Melanoma Cohort
Required histologic types
Melanoma
Required histologic sub types
Nodular melanoma
Lentigo maligna melanoma
Superficial spreading melanoma
Acral lentiginous melanoma
Achromic melanoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Daiichi Sankyo
Phase 2
Skin cancer
#NCT05561634
Required histologic types
Basal cell carcinoma
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Radiotherapy
2 recruiting sites
CHU Lille
Phase 2
Sarcoma and GIST
#NCT07507773
Required histologic types
Soft tissue sarcoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
1 recruiting site
Centre Oscar Lambret
Phase 2
Multiple myeloma
#NCT07227311
#2025-523117-28-00
Cohorte BVd (Belantamab mafodotin + Bortezomib + Dexamethasone)
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
1
2
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
6 recruiting sites
GlaxoSmithKline
Phase 2
Multiple myeloma
#NCT07227311
#2025-523117-28-00
Cohorte BKd (Belantamab mafodotin + Carfilzomib + dexaméthasone)
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
1
2
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
6 recruiting sites
GlaxoSmithKline
Phase 2
Multiple myeloma
#NCT07227311
#2025-523117-28-00
Cohorte BPd (Belantamab + Pomalidomide + Dexamethasone))
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
1
2
Required previous treatments
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
6 recruiting sites
GlaxoSmithKline
Phase 2
Lung cancer
#NCT07234058
#2024-519208-29-00
Required histologic types
Mesothelium
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
17 recruiting sites
Intergroupe Francophone de Cancérologie Thoracique